SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination with GSK's pandemic adjuvant following positive interim Phase 1/2 results.

from Breaking World Pharma News https://ift.tt/3gOx10a